BACKGROUND: Mass azithromycin distributions are effective for clearing ocular strains of Chlamydia trachomatis, yet infection frequently returns in areas with hyperendemic trachoma. A better understanding of the factors associated with chlamydial reinfection could be helpful to plan trachoma elimination strategies. METHODS: This was a prospective cohort study conducted in a trachoma-hyperendemic region of Ethiopia in 2003. As part of a larger cluster-randomized trial, 21 villages were treated with a single mass azithromycin distribution and all children 5 years and younger were monitored for ocular chlamydia and clinically active trachoma at baseline and at 2 and 6 months following the treatment. RESULTS: In 20 villages with available data, azithromycin treatment coverage was 88.7% (95% confidence interval [CI] 85.7-91.8%). In total, 1005 children tested negative for ocular chlamydia at the 2-month visit, of whom 41 became infected by 6 months (1.0 incident chlamydia infections per 100 person-months, 95%CI 0.7-1.4). The presence of intense trachomatous inflammation (TI) at baseline was associated with incident infection at 6 months (incidence rate ratio 1.91, 95%CI 1.03-3.55). Ocular chlamydia infections clustered more within households than communities: (intraclass correlation coefficient 0.01 for communities and 0.29 for households six months posttreatment). Younger children were more likely to have persistent clinically active trachoma (P = 0.03). CONCLUSIONS: More intensive antibiotic distributions may be warranted for younger children, for children with TI, and for households containing children with ocular chlamydia infections.
RCT Entities:
BACKGROUND: Mass azithromycin distributions are effective for clearing ocular strains of Chlamydia trachomatis, yet infection frequently returns in areas with hyperendemic trachoma. A better understanding of the factors associated with chlamydial reinfection could be helpful to plan trachoma elimination strategies. METHODS: This was a prospective cohort study conducted in a trachoma-hyperendemic region of Ethiopia in 2003. As part of a larger cluster-randomized trial, 21 villages were treated with a single mass azithromycin distribution and all children 5 years and younger were monitored for ocular chlamydia and clinically active trachoma at baseline and at 2 and 6 months following the treatment. RESULTS: In 20 villages with available data, azithromycin treatment coverage was 88.7% (95% confidence interval [CI] 85.7-91.8%). In total, 1005 children tested negative for ocular chlamydia at the 2-month visit, of whom 41 became infected by 6 months (1.0 incident chlamydia infections per 100 person-months, 95%CI 0.7-1.4). The presence of intense trachomatous inflammation (TI) at baseline was associated with incident infection at 6 months (incidence rate ratio 1.91, 95%CI 1.03-3.55). Ocular chlamydia infections clustered more within households than communities: (intraclass correlation coefficient 0.01 for communities and 0.29 for households six months posttreatment). Younger children were more likely to have persistent clinically active trachoma (P = 0.03). CONCLUSIONS: More intensive antibiotic distributions may be warranted for younger children, for children with TI, and for households containing children with ocular chlamydia infections.
Authors: Sintayehu Gebresillasie; Zerihun Tadesse; Ayalew Shiferaw; Sun N Yu; Nicole E Stoller; Zhaoxia Zhou; Paul M Emerson; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan Journal: Ophthalmic Epidemiol Date: 2015 Impact factor: 1.648
Authors: Nakul Shekhawat; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Laura Dize; Thomas C Quinn; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2014-04-11 Impact factor: 4.799
Authors: Muluken Melese; Wondu Alemayehu; Takele Lakew; Elizabeth Yi; Jenafir House; Jaya D Chidambaram; Zhaoxia Zhou; Vicky Cevallos; Kathryn Ray; Kevin Cyrus Hong; Travis C Porco; Isabella Phan; Ali Zaidi; Bruce D Gaynor; John P Whitcher; Thomas M Lietman Journal: JAMA Date: 2008-02-20 Impact factor: 56.272
Authors: Jaya D Chidambaram; Wondu Alemayehu; Muluken Melese; Takele Lakew; Elizabeth Yi; Jenafir House; Vicky Cevallos; Zhaoxia Zhou; Kathryn Maxey; David C Lee; Brett L Shapiro; Muthiah Srinivasan; Travis Porco; John P Whitcher; Bruce D Gaynor; Thomas M Lietman Journal: JAMA Date: 2006-03-08 Impact factor: 56.272
Authors: Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2005-01 Impact factor: 4.799
Authors: Sheila K West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Allen Foster; Robin L Bailey; David C W Mabey Journal: Lancet Date: 2005-10-08 Impact factor: 79.321
Authors: Berhan Ayele; Teshome Gebre; Jeanne Moncada; Jenafir I House; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Jeremy D Keenan Journal: PLoS Negl Trop Dis Date: 2011-12-13
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26